Mark Fuerst
Abstract
More accurate identification of molecular subtyping for breast cancer may be able to identify patients with chemosensitivity to specific therapies, according to a new study.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
More accurate identification of molecular subtyping for breast cancer may be able to identify patients with chemosensitivity to specific therapies, according to a new study.
Key concepts: Subtyping, Breast cancer, Oncology, Chemosensitivity assay, Biology, Cancer research, Medicine, Cancer